Overview

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Henlius Biotech